Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Vermont
Age
18–95
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically proven breast cancer
Pre or post-menopausal
Age \>18
Completed adjuvant non-hormonal therapy \>30 days prior to initiation of study (surgery and/or chemotherapy and/or radiation therapy)
Platelet count and hemoglobin within normal ranges for local lab within 30 days of initiation of study therapy
Receiving tamoxifen therapy for at least 90 days prior to initiation of study therapy, and is expected to continue that therapy for the duration of the study (75 days)
You may not be if
Chemotherapy, radiation therapy or surgery within 30 days of study therapy
Current use of aspirin, anti-platelet or anti-coagulation agents on a continuous basis
Prior history of gastrointestinal or central nervous system bleeding, or documented or self-reported blood in stools or bright red blood per rectum
Clareo Health | The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy
